Sanofi: stock sanctioned after bid for Bioverativ
(CercleFinance.com) - Sanofi is currently the trailer in the CAC40, down 2.
8%, suffering from the announcement of an agreement for the acquisition of Bioverativ at a price of 105 per share, representing a cash transaction that is worth approximately 11.6 billion dollars.
Bryan Garnier, which has placed its "neutral" rating on the Sanofi stock "under review," along with its fair value of 84 euros, underlines that the price offered implies a premium of 64% relative to Bioverativ's share price at close last Friday.
"We will assess more carefully the impact of what Sanofi is acquiring but the field in which it invests makes sense regarding its overall strategy consisting of making haemophilia a priority," the broker says.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.
8%, suffering from the announcement of an agreement for the acquisition of Bioverativ at a price of 105 per share, representing a cash transaction that is worth approximately 11.6 billion dollars.
Bryan Garnier, which has placed its "neutral" rating on the Sanofi stock "under review," along with its fair value of 84 euros, underlines that the price offered implies a premium of 64% relative to Bioverativ's share price at close last Friday.
"We will assess more carefully the impact of what Sanofi is acquiring but the field in which it invests makes sense regarding its overall strategy consisting of making haemophilia a priority," the broker says.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.